Biofidelity's mission is to enable the early detection of disease and to improve patient outcomes through the implementation of simple yet ultra-high sensitivity diagnostic assays based on our proprietary biochemistry. We have developed a novel molecular assay enabling the multiplexed detection of genetic mutations at extremely high sensitivity (<0.1% allele fraction) from tissue or blood samples, without the need for DNA sequencing. Using standard laboratory instrumentation, our assays are simple, fast, scalable and low-cost, enabling rapid implementation and broad adoption. The simplicity of this technology makes it particularly suited to routine testing applications, including patient monitoring for disease recurrence and developed resistance to therapy, and to early detection of disease.